Go to the page content

Calculați-vă IMC

cm
ft
in
kg
st
lb

Your BMI:

__

Your weight classification:

__

Underweight

Being underweight could be a sign you're not eating enough or that you may be ill.

If you're underweight, contact your general practitioner for further evaluation.

Normal weight

The medical community recommends that you keep your weight within this range.

Overweight

People who fall into this category may be at risk of developing obesity. They might also be at risk of developing other health problems, or that their current health problems may worsen. The recommendation is to consult a healthcare provider trained in obesity management.

There are two recommendations for people who fall into the pre-obesity category, which are recommended by European23 and American24 clinical guidelines for obesity management in adults.

The recommendation for people with a BMI between 25.0 and 29.9 who do not have weight-related health problems (i.e. high blood pressure or high cholesterol) is to prevent further weight gain through healthy eating and increased physical activity.23

For people with a BMI between 27 and 29.0, who also have weight-related health problems, the recommendation is to lose weight by combining lifestyle interventions and anti-obesity medications to achieve weight loss and improve health and quality of life.23,24

Obesity I

People with a BMI of 30 or above may have obesity, which is defined as an abnormal or excessive accumulation of fat25 that may harm health. Today, a number of health organisations recognise obesity as a chronic, but manageable disease.23

The World Health Organisation and other health organisations distinguish three classes of obesity:

 Obesity Classification    BMI

 Class I                                30.0–34.9

 Class II                               35.0–39.9

 Class III                              Above 40

The BMI ranges are based on the effect that excessive body fat has on individuals’ health, life expectancy and risk of developing diseases. As BMI increases, so does the risk for some diseases.26

It’s recommended that people with a BMI of 30 or above consult a healthcare provider trained in obesity management for diagnosis, risk assessment and treatment of obesity and weight-related health complications.

The goal of managing and treating obesity is not simply to lose weight, but instead to improve health and lower the risks of other health complications. Even losing as little as five percent of body weight – and maintaining this weight loss – can improve overall wellbeing, while also reducing the risk of weight-related complications.27

There’s a range of scientifically proven treatment options for obesity that may be recommended depending on individual needs, health status and the presence or absence of weight-related complications. Treatment may include a combination of the following options*:

* Disclaimer: This information is not a substitute for the advice of a healthcare provider. If you have any questions regarding your health, you should contact your general practitioner or another qualified healthcare provider.

Obesity II

People with a BMI of 30 or above may have obesity, which is defined as an abnormal or excessive accumulation of fat25 that may harm health. Today, a number of health organisations recognise obesity as a chronic, but manageable disease.23

The World Health Organisation and other health organisations distinguish three classes of obesity:

Obesity Classification    BMI

 Class I                                30.0–34.9

 Class II                               35.0–39.9

 Class III                              Above 40

The BMI ranges are based on the effect that excessive body fat has on individuals’ health, life expectancy and risk of developing diseases. As BMI increases, so does the risk for some diseases.26

It’s recommended that people with a BMI of 30 or above consult a healthcare provider trained in obesity management for diagnosis, risk assessment and treatment of obesity and weight-related health complications.

The goal of managing and treating obesity is not simply to lose weight, but instead to improve health and lower the risks of other health complications. Even losing as little as five percent of body weight – and maintaining this weight loss – can improve overall wellbeing, while also reducing the risk of weight-related complications.27

There’s a range of scientifically proven treatment options for obesity that may be recommended depending on individual needs, health status and the presence or absence of weight-related complications. Treatment may include a combination of the following options*:

* Disclaimer: This information is not a substitute for the advice of a healthcare provider. If you have any questions regarding your health, you should contact your general practitioner or another qualified healthcare provider.

Obesity III

People with a BMI of 30 or above may have obesity, which is defined as an abnormal or excessive accumulation of fat25 that may harm health. Today, a number of health organisations recognise obesity as a chronic, but manageable disease.23

The World Health Organisation and other health organisations distinguish three classes of obesity:

Obesity Classification    BMI

 Class I                             30.0–34.9

 Class II                            35.0–39.9

 Class II                            Above 40

The BMI ranges are based on the effect that excessive body fat has on individuals’ health, life expectancy and risk of developing diseases; as BMI increases, so does the risk for some diseases.26

It’s recommended that people with a BMI of 30 or above consult a healthcare provider trained in obesity management for diagnosis, risk assessment and treatment of obesity and weight-related health complications.

The goal of managing and treating obesity is not simply to lose weight, but instead to improve health and lower the risks of other health complications. Even losing as little as five percent of body weight – and maintaining this weight loss – can improve overall wellbeing, while also reducing the risk of weight-related complications.27

There’s a range of scientifically proven treatment options for obesity that may be recommended depending on individual needs, health status and the presence or absence of weight-related complications. Treatment may include a combination of the following options*:

* Disclaimer: This information is not a substitute for the advice of a healthcare provider. If you have any questions regarding your health, you should contact your general practitioner or another qualified healthcare provider.

    @




    A link with your BMI result has been sent to the email address.
    An error has occured. The email wasn't sent.

    Măsurați-vă IMC cu calculatorul IMC


    Calculatorul IMC vă împarte greutatea, exprimată în kg, la pătratul înălțimii, exprimate în metri. Vedeți unde se încadrează valoarea dumneavoastră a IMC în clasele de IMC de mai jos. Faceți clic pe o clasă de IMC pentru a afla mai multe.

     

    Clasificare

     

    IMC este exprimat în kg/m2

    Subponderalitate

    Sub 18,5

    Normal

    18,5-24,9

    Supraponderalitate

    25,0-29,9

    Obezitate

    30 și peste

    Clasa I

    30,0-34,9

    Clasa II

    35,0-39,9

    Clasa III

    40 și peste

    *Acest calculator IMC este pentru adulți cu vârsta de 20 de ani sau mai mare. Dacă aveți vârsta sub 20 de ani, discutați cu medicul dumneavoastră despre valoarea dumneavoastră a IMC.

    De ce este important să cunoaștem IMC?

    IMC este o modalitate bună de a verifica riscul bolilor legate de grăsimea corporală. Faptul de a trăi cu supraponderalitate sau obezitate este asociat cu alte boli și cu un risc crescut de mortalitate.1 În general, cu cât mai mare este valoarea IMC, cu atât mai mare este riscul de a dezvolta alte boli cronice legate de obezitate, inclusiv:

    • Diabet zaharat de tip 2 2
    • Boli cardiovasculare3 precum boala coronariană4
    • Accident vascular cerebral și infarct miocardic (IM)5
    • Hipertensiune arterială6
    • Infertilitate7
    • Depresie8 și anxietate9
    • Dislipidemie10
    • Boala ficatului gras non-alcoolic (NAFLD – non-alcoholic fatty liver disease) / steatohepatită non-alcoolică (NASH - non-alcoholic steatohepatitis)11
    • Boală de reflux gastro-esofagian (BRGE)12
    • Sindrom metabolic (MetS – metabolic syndrome)13
    • Incontinență urinară14
    • Apnee obstructivă în somn și probleme de respirație15
    • Boală cronică de rinichi16
    • Diverse tipuri de cancer: inclusiv (fără a se limita la) cancer de sân, de colon, endometrial, esofagian, renal, ovarian, și pancreatic17
    • Osteoartrita genunchiului18
    • Boală litiazică biliară19
    • Tromboză20
    • Gută21
    • Risc crescut de mortalitate comparativ cu persoanele cu o valoare sănătoasă a IMC22

    Solicitați medicului dumneavoastră mai multe informații despre oricare dintre aceste boli și despre modul în care sunt legate de valoarea dumneavoastră a IMC.

    4 recomandări pentru o gestionare mai bună a greutății corporale

    Care sunt limitele IMC?

    IMC este o măsurătoare simplă și obiectivă, însă poate induce în eroare în unele cazuri și pentru unele grupuri de persoane. Cercetările au arătat că IMC este mai puțin precis în predicția riscului de boală la persoane cu vârstă mai înaintată, sportivi, persoanele foarte înalte sau foarte scunde, precum și la persoanele cu constituție corporală mai musculoasă. De exemplu, sportivii de elită sau culturiștii au mai mulți mușchi și cântăresc mai mult, ceea ce face să aibă o valoare IMC mai mare.

    Intervalele IMC variază între diferite regiuni și la diferite populații. De exemplu, valorile limită pentru populațiile indiene sau japoneze diferă de cele ale populațiilor occidentale.

    De asemenea, IMC nu ia în considerare nici următorii factori:

    • Factori de risc ereditari asociați cu boli legate de obezitate, precum sindromul metabolic
    • Factori de mediu sau de stil de viață, alții decât obezitatea, care pot contribui la riscul dumneavoastră de a dezvolta boli cronice
    • Modul în care este distribuită grăsimea corporală la diferite persoane

    Este important să vă amintiți că faptul de a trăi cu obezitate nu înseamnă neapărat că sunteți nesănătos/nesănătoasă, la fel cum faptul de a avea  greutate „normală” nu înseamnă neapărat că sunteți sănătos/sănătoasă. Valoarea dumneavoastră a IMC nu vă definește, însă cunoașterea și  înțelegerea IMC pot reprezenta un instrument util în preluarea inițiativei asupra stării dumneavoastră de sănătate.

    Indiferent de valoarea dumneavoastră a IMC, profesioniștii din domeniul sănătății recomandă o dietă sănătoasă și un stil de viață sănătos. Vorbiți cu medicul dumneavoastră despre greutatea dumneavoastră și evaluați acțiunile potențial necesare.

    Citiți mai multe despre tratamentul diabetului zaharat și faptul de a trăi cu diabet zaharat

    A trăi cu diabet zaharat

    A trăi cu diabet zaharat

    A fi diagnosticat cu diabet zaharat poate fi copleșitor inițial, însă acceptarea diagnosticului dumneavoastră și gestionarea afecțiunii este un obiectiv realizabil. Motivația, educația, tehnologia și susținerea reprezintă factori esențiali în faptul de a trăi cu diabet zaharat.

    Tratamentul diabetului zaharat
    1 min. read

    Tratamentul diabetului zaharat

    Există numeroase modalități de tratament al diabetului zaharat. Stilul de viață, insulina și alternativele la insulină au roluri esențiale în faptul de a trăi cu diabet zaharat de tip 1 și de tip 2.

    RO25RYB00148/ Mai 2025

    Referințe
    1. Abdelaal M, le Roux CW, Docherty NG. Morbidity and mortality associated with obesity. Ann Transl Med. 2017 Apr;5(7):161. doi: 10.21037/atm.2017.03.107. PMID: 28480197; PMCID: PMC5401682.
    2. Hussain, A et al, “Type 2 Diabetes and obesity: A review” Journal of Diabetology, June 2010; 2:1
    3. Katzmarzyk, P T et al, “Body mass index and risk of cardiovascular disease, cancer and all-cause mortality” Can. J. Public Health, vol. 103, no. 2, pp. 147–151, 2012, doi:10.1007/BF03404221.
    4. Lamon-Fava, S et al, “Impact of Body Mass Index on Coronary Heart Disease Risk Factors in Men and Women,” Arterioscler. Thromb. Vasc. Biol., vol. 16, no. 12, pp. 1509–1515, Dec. 1996, doi: 10.1161/01.ATV.16.12.1509.
    5. Kurth, T et al, “Prospective Study of Body Mass Index and Risk of Stroke in Apparently Healthy Women,” Circulation, vol. 111, no. 15, pp. 1992–1998, Apr. 2005, doi:10.1161/01.CIR.0000161822.83163.B6.
    6. Landi, F et al, “Body Mass Index is Strongly Associated with Hypertension: Results from the Longevity Check-Up 7+ Study” Nutrients. 2018 Dec; 10(12): 1976. Published online 2018 Dec 13. doi: 10.3390/nu10121976
    7. Dağ, Z Ö et al, “Impact of obesity on infertility in women,” J. Turkish Ger. Gynecol. Assoc., vol. 16, no. 2, pp. 111–117, Jun. 2015, doi: 10.5152/jtgga.2015.15232.
    8. Moussa, O M et al, “Effect of body mass index on depression in a UK cohort of 363037 obese patients: A longitudinal analysis of transition,” Clin. Obes., vol. 9, no. 3, p. e12305, Jun. 2019, doi: https://doi.org/10.1111/cob.12305.
    9. Zhao, G et al, “Depression and anxiety among US adults: associations with body mass index,” Int. J. Obes., vol. 33, no. 2, pp. 257–266, 2009, doi: 10.1038/ijo.2008.268.
    10. Van Hemelrijck, M et al, “Longitudinal study of body mass index, dyslipidemia, hyperglycemia, and hypertension in 60,000 men and women in Sweden and Austria” Published: June 13, 2018https://doi.org/10.1371/journal.pone.0197830
    11. Loomis, A K et al, “Body Mass Index and Risk of Nonalcoholic Fatty Liver Disease: Two Electronic Health Record Prospective Studies,” J. Clin. Endocrinol. Metab., vol. 101, no.3, pp. 945–952, Mar. 2016, doi: 10.1210/jc.2015-3444.
    12. Zafar, S et al, “Correlation of gastroesophageal reflux disease symptoms with body mass index,” Saudi J. Gastroenterol., vol. 14, no. 2, pp. 53–57, Apr. 2008, doi: 10.4103/1319-3767.39618.
    13. Han, T S et al, “A clinical perspective of obesity, metabolic syndrome and cardiovascular disease,” JRSM Cardiovasc. Dis., vol. 5, pp. 2048004016633371–2048004016633371, Feb. 2016, doi: 10.1177/2048004016633371.
    14. Subak, L L et al, “Obesity and Urinary Incontinence: Epidemiology and Clinical Research Update” J Urol. 2009 Dec; 182(6 Suppl): S2–S7 doi: 10.1016/j.juro.2009.08.071
    15. Romero-Corral, A et al, “Interactions Between Obesity and Obstructive Sleep Apnea - Implications for Treatment” Chest. 2010 Mar; 137(3): 711–719. doi: 10.1378/chest.09-0360
    16. Herrington, W G et al, “Body-mass index and risk of advanced chronic kidney disease: Prospective analyses from a primary care cohort of 1.4 million adults in England,” PLoS One, vol. 12, no. 3, p. e0173515, Mar. 2017, [Online]. Available: https://doi.org/10.1371/journal.pone.0173515.
    17. Bhaskaran, K et al, “Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5.24 million UK adults,” Lancet, vol. 384, no. 9945, pp. 755–765, Aug. 2014, doi: 10.1016/S0140-6736(14)60892-8.
    18. Zheng, H et al, “Body mass index and risk of knee osteoarthritis: Systematic review and meta-analysis of prospective studies,” BMJ Open, vol. 5, no. 12, 2015, doi: 10.1136/bmjopen-2014-007568.
    19. Su, Y P et al, “Strong association between metabolically-abnormal obesity and gallstone disease in adults under 50 years” BMC Gastroenterol 19, 117 (2019). https://doi.org/10.1186/s12876-019-1032-y
    20. Yang, G et al, “The effects of obesity on venous thromboembolism: A review” Open J Prev Med. 2012 Nov; 2(4): 499–509. doi: 10.4236/ojpm.2012.24069
    21. Bai, L et al, “Incident gout and weight change patterns: a retrospective cohort study of US adults” Arthritis Res Ther. 2021; 23: 69. Published online 2021 Mar 2. doi: 10.1186/s13075-021-02461-7
    22. Klatsky, A L et al, “Body Mass Index and Mortality in a Very Large Cohort: Is It Really Healthier to Be Overweight?,” Perm. J., vol. 21, pp. 16–142, 2017, doi: 10.7812/TPP/16-142.
    23. Yumuk, V et al, “European Guidelines for Obesity Management in Adults” Obes Facts. 2015 Dec; 8(6): 402–424. Published online 2015 Dec 5. doi: 10.1159/000442721
    24. Garvey, W T et al, “American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity.” Endocrine Practice 2016;22:1–203.
    25. Rueda-Clausen, C F et al, “Assessment of People Living with Obesity,” Can. Adult Obes. Clin. Pract. Guidel., pp. 1–17, 2020, [Online]. Available: http://obesitycanada.ca/wpcontent/uploads/2020/09/6-Obesity-Assessment-v5-with-links.pdf
    26. Guh, D P et al, “The incidence of co-morbidities related to obesity and overweight: A systematic review and meta-analysis,” BMC Public Health, vol. 9, no. 1, p. 88, 2009, doi:10.1186/1471-2458-9-88.
    27. Ryan DH, Yockey SR. Weight Loss and Improvement in Comorbidity: Differences at 5%, 10%, 15%, and Over. Curr Obes Rep. 2017 Jun;6(2):187-194. doi: 10.1007/s13679-017-0262-y. PMID: 28455679; PMCID: PMC5497590.